The US Food and Drug Administration (FDA) has granted clearance to Abbott’s new cardiac mapping platform, EnSite X EP System with EnSite Omnipolar Technology (OT), which is designed to help physicians treat cardiac arrhythmias.
Available in the US and across Europe, the system is designed to create detailed 3D maps of the heart that allow surgeons to identify and treat areas where arrhythmias originate.
The device includes the company’s EnSite OT, which uses the Advisor HD Grid Catheter to provide true electrograms (EGMs) regardless of catheter orientation in the heart.
